Search results for " Mutation"

showing 10 items of 1212 documents

Detection of DNA effects in human cells with the comet assay and their relevance for mutagenesis

1996

The single cell gel test (SCG-test or comet assay) is a rapid and sensitive method for measuring DNA damage and repair in individual cells. A wide variety of mutagens have been shown to cause DNA alterations detectable with the comet assay, but it is not yet clear whether a relationship exists between the DNA effects and the induction of mutations. We are therefore investigating in a cell culture system with human cells (MRC5CV1) the induction of DNA damage by environmental mutagens and the formation of mutations at the HPRT gene. In the present study we investigated benzo[a]pyrene (BP), an environmental mutagenic and carcinogenic polycyclic aromatic hydrocarbon, and its reactive metabolite…

Hypoxanthine PhosphoribosyltransferaseDNA repairDNA damageCytological TechniquesMutagenGene mutationToxicologymedicine.disease_causechemistry.chemical_compoundBenzo(a)pyrenemedicineHumansCell Line TransformedElectrophoresis Agar GelGeneticsCell DeathMutagenesisfood and beveragesGeneral MedicineMolecular biologyComet assaychemistryMutagenesisEnvironmental PollutantsDNAGenotoxicityDNA DamageToxicology Letters
researchProduct

IMMUNOHISTOCHEMICAL DETECTION OF BRAF V600E MUTATION IN AMELOBLASTOMA

2021

IMMUNOHISTOCHEMICAL BRAF V600E MUTATION AMELOBLASTOMA
researchProduct

Impaired Binding to Junctophilin-2 and Nanostructural Alteration in CPVT Mutation

2021

Rationale: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare disease, manifested by syncope or sudden death in children or young adults under stress conditions. Mutations in the Ca 2+ release channel/RyR2 (type 2 ryanodine receptor) gene account for about 60% of the identified mutations. Recently, we found and described a mutation in RyR2 N-terminal domain, RyR2 R420Q . Objective: To determine the arrhythmogenic mechanisms of this mutation. Methods and Results: Ventricular tachycardias under stress conditions were observed in both patients with catecholaminergic polymorphic ventricular tachycardia and knock-in mice. During action potential recording (by patch-clamp in …

Ile de francePhysiologyCPVT030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineaction potential[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPolitical sciencejunctophilinryanodine receptormedia_common.cataloged_instanceHumansEuropean union610 Medicine & health030304 developmental biologymedia_common0303 health sciencescalciumRyanodine Receptor Calcium Release ChannelRyR2musculoskeletal systemSarcoplasmic ReticulumDeath Sudden Cardiaccalcium induced calcium releaseGain of Function Mutationcardiomyocyte calcium handlingcardiovascular systemventricular tachycardiamutationCardiology and Cardiovascular MedicineHumanities
researchProduct

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations

2005

Activating mutations of Flt3 are found in approximately one third of patients with acute myeloid leukemia (AML) and are an attractive drug target. Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD). We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of signal transducer and activator of transcription 5 (STAT5) and repression of CCAAT/estradiol-binding protein α (c/EBPα) and Pu.1. Here, we compared the signaling properties of Flt3-ITD versus Flt3-TKD in myeloid progenitor cells. We demonstrate that Flt3-TKD mutations induced autonomous growth of 32D ce…

ImmunologyApoptosisBiologymedicine.disease_causeBiochemistryCell Linefluids and secretionsProto-Oncogene Proteinshemic and lymphatic diseasesSTAT5 Transcription FactormedicineAnimalsHumansPoint MutationMyeloid CellsPhosphorylationProtein kinase BProtein kinase CMutationPoint mutationAutophosphorylationIntracellular Signaling Peptides and ProteinsReceptor Protein-Tyrosine Kinaseshemic and immune systemsCell BiologyHematologyMilk ProteinsStaurosporineMolecular biologyProtein Structure TertiaryDNA-Binding ProteinsMuridaefms-Like Tyrosine Kinase 3Leukemia MyeloidTandem Repeat SequencesAcute Diseaseembryonic structuresFms-Like Tyrosine Kinase 3Mutagenesis Site-DirectedTrans-ActivatorsSignal transductionTyrosine kinaseSignal TransductionTranscription FactorsBlood
researchProduct

Molecular basis of filamin a-filGAP interaction and its impairment in congenital disorders associated with filamin a mutations

2008

Background Mutations in filamin A (FLNa), an essential cytoskeletal protein with multiple binding partners, cause developmental anomalies in humans. Methodology/Principal Findings We determined the structure of the 23rd Ig repeat of FLNa (IgFLNa23) that interacts with FilGAP, a Rac-specific GTPase-activating protein and regulator of cell polarity and movement, and the effect of the three disease-related mutations on this interaction. A combination of NMR structural analysis and in silico modeling revealed the structural interface details between the C and D β-strands of the IgFLNa23 and the C-terminal 32 residues of FilGAP. Mutagenesis of the predicted key interface residues confirmed the b…

ImmunoprecipitationFilaminsMolecular Sequence Dataeducationlcsh:MedicineComputational Biology/Protein Structure PredictionBiologyFilaminCell Biology/Cell SignalingCongenital AbnormalitiesBiochemistry/Protein Folding03 medical and health sciences0302 clinical medicineProtein structureContractile ProteinsCell Biology/CytoskeletonFLNAHumansFLNBFLNCAmino Acid Sequencelcsh:Science030304 developmental biologyGenetics0303 health sciencesMultidisciplinaryBinding SitesMolecular StructureSequence Homology Amino AcidPoint mutationlcsh:RGTPase-Activating ProteinsMicrofilament Proteins3. Good healthBiochemistry/BioinformaticsMutationProtein foldinglcsh:Q118 Biological sciences030217 neurology & neurosurgeryResearch Article
researchProduct

Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study

2019

Ataluren was reported to suppress nonsense mutations by promoting the readthrough of premature stop codons, although its mechanism of action (MOA) is still debated. The likely interaction of Ataluren with CFTR-mRNA has been previously studied by molecular dynamics. In this work we extended the modeling of Ataluren's MOA by complementary computational approaches such as induced fit docking (IFD), quantum polarized ligand docking (QPLD), MM-GBSA free-energy calculations, and computational mutagenesis. In addition to CFTR-mRNA, this study considered other model targets implicated in the translation process, such as eukaryotic rRNA 18S, prokaryotic rRNA 16S, and eukaryotic Release Factor 1 (eRF…

In silicoNonsense mutationComputational biology01 natural sciencesRibosomeBiochemistrychemistry.chemical_compoundDrug DiscoveryQPLDcomputational mutagenesiMM-GBSA010405 organic chemistryChemistryDrug Discovery3003 Pharmaceutical ScienceOrganic Chemistrypremature termination codonSettore CHIM/06 - Chimica OrganicaSettore CHIM/08 - Chimica FarmaceuticaStop codon0104 chemical sciencesAtalurenInduced fit docking010404 medicinal & biomolecular chemistrySettore BIO/18 - GeneticaDocking (molecular)ProofreadingRelease factoroxadiazole
researchProduct

TERT promoter mutation subtypes in 20 in-situ melanomas

2019

In situCancer ResearchSkin NeoplasmsDermatologyBiologyPrognosisMolecular biologyOncologyMutationBiomarkers TumorHumansTert promoter mutationPromoter Regions GeneticMelanomaTelomeraseCarcinoma in SituMelanoma Research
researchProduct

Geldanamycin and its derivatives as Hsp90 inhibitors

2012

The Hsp90 molecule, one of the most abundant heat shock proteins in mammalian cells, maintains homeostasis and prevents stress-induced cellular damage. Hsp90 is expressed under normal conditions at a level of about 1-2 Percent of total proteins, while its expression increases 2-10 fold in cancer cells. The two main constitutively expressed isoforms of Hsp90 are known as Hsp90-alpha and Hsp90-beta, and their upregulation is associated with tumor progression, invasion and formation of metastases, as well as development of drug resistance. The Hsp90 is a key target for many newly established, potent anticancer agents containing Hsp90 N-terminal ATP binding inhibitors, such as geldanamycin, and…

IndolesLactams MacrocyclicCyclin-Dependent KinaseAntineoplastic AgentsTanespimycinBenzoquinoneModels BiologicalAntineoplastic Agentchemistry.chemical_compoundDownregulation and upregulationTransforming Growth Factor betaCyclin-dependent kinaseHeat shock proteinBenzoquinonespolycyclic compoundsAnimalsHumansHSP90 Heat-Shock ProteinsbiologyAnimalTriazolesGeldanamycinHsp90Cyclin-Dependent KinasesProto-Oncogene Proteins c-rafHSP90 Heat-Shock Proteinsrc-Family KinaseschemistryTumor progressionMutationCancer cellbiology.proteinCancer researchMacrolidesMacrolideTriazoleTumor Suppressor Protein p53Animals; Antineoplastic Agents; Benzoquinones; Cyclin-Dependent Kinases; HSP90 Heat-Shock Proteins; Humans; Lactams Macrocyclic; Macrolides; Models Biological; Mutation; Novobiocin; Proto-Oncogene Proteins c-raf; Transforming Growth Factor beta; Triazoles; Tumor Suppressor Protein p53; src-Family KinasesNovobiocinHumanFrontiers in Bioscience
researchProduct

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)…

2015

Abstract Background: Luspatercept is a fusion protein (modified activin receptor IIB-IgG Fc) being investigated for the treatment of anemias with ineffective erythropoiesis. MDS patients have increased Smad2/3 signaling in the bone marrow, leading to ineffective erythropoiesis. Luspatercept inhibits Smad2/3 signaling and promotes late-stage erythroid differentiation, thereby correcting ineffective erythropoiesis. Aims: This completed, 3-month, phase 2, multicenter, open-label study evaluated the effects of luspatercept on anemia in patients with low/int-1 risk MDS (IPSS classification). Study outcomes include erythroid response of increased hemoglobin (Hb) in low transfusion burden (LTB) pa…

Ineffective erythropoiesisOncologymedicine.medical_specialtyAnemiaImmunologyPopulationGene mutationmedicine.disease_causeLower riskBiochemistry03 medical and health sciences0302 clinical medicineInternal medicineMedicineeducationLenalidomideeducation.field_of_studybusiness.industryMyelodysplastic syndromesCell BiologyHematologymedicine.disease3. Good healthSurgery030220 oncology & carcinogenesisAbsolute neutrophil countbusiness030215 immunologymedicine.drugBlood
researchProduct

CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders

2013

International audience; BACKGROUND:The high frequency of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene mutation p.Arg117His in patients with congenital bilateral absence of the vas deferens (CBAVD) and in newborns screened for CF has created a dilemma.METHODS:Phenotypic and genotypic data were retrospectively collected in 179 non-newborn French individuals carrying p.Arg117His and a second CFTR mutation referred for symptoms or family history, by all French molecular genetics laboratories, referring physicians, CF care centres and infertility clinics.RESULTS:97% of the patients had the intronic T7 normal variant in cis with p.Arg117His. 89% patients were male, wit…

InfertilityMalemedicine.medical_specialtyHeterozygoteCystic FibrosisOffspring[SDV]Life Sciences [q-bio]Cystic Fibrosis Transmembrane Conductance RegulatorGene mutationCompound heterozygosityAsymptomaticCystic fibrosis03 medical and health sciences0302 clinical medicineVas DeferensMale Urogenital DiseasesMutation RateInternal medicinePrenatal DiagnosisGenotypeGeneticsmedicineHumansFamily historyChildSweatGenetics (clinical)Infertility Male030304 developmental biology0303 health sciencesbusiness.industryInfant NewbornInfantmedicine.disease3. Good healthPhenotype030228 respiratory systemChild PreschoolImmunologyMutationFemalemedicine.symptombusiness
researchProduct